Blue ConnectWe'll be completing scheduled maintenance beginning Saturday at 10 p.m. continuing through Sunday afternoon. Blue Connect may be unavailable during this time.
Medical Policy Update For December 30, 2021
| Policy Name | Revised Criteria |
| Aducanumab-avwa (Aduhelm™) | Added HCPCS code J0172 to dosing reference table effective 1/1/2022, deleted C9399, J3490, and J3590 termed 12/31/2021. Blue Cross NC Pharmacy and Therapeutics Committee 6/29/2021. |
| Anifrolumab-fnia (Saphnelo™) | Added HCPCS code C9086 to dosing reference table effective 1/1/2022, deleted C9399 termed 12/31/2021. Blue Cross NC Pharmacy and Therapeutics Committee 12/21/2021. |
| CAR-T Therapy | Added HCPCS code Q2055 and description to dosing reference section for Abecma effective 1/1/2022, deleted C9081, J3490, J3590, and J9999 termed 12/31/2021. Blue Cross NC Pharmacy and Therapeutics Committee 6/29/2021. |
| Dostarlimab-gxly (Jemperli®) | Added HCPCS code J9272 to dosing reference table effective 1/1/2022, deleted C9082, J3490, J3590, and J9999 termed 12/31/2021. Blue Cross NC Pharmacy and Therapeutics Committee 12/21/2021. |
| Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders | Added HCPCS code C9085 to dosing reference table for Nexviazyme effective 1/1/2022, deleted C9399 termed 12/31/2021. Blue Cross NC Pharmacy and Therapeutics Committee 12/21/2021. |
| White Blood Cell Growth Factors | Added HCPCS code J2506 to Billing/Coding section effective 1/1/2022, J2505 to be termed 12/31/2021. |